Is there a role for local therapy alone in treatment of high grade prostate cancer?: Assessment of outcome with radical prostatectomy

Abstract

Patients with high-grade clinically localized disease often have disease beyond the prostate and if so are likely to fail treatment with radical prostatectomy or radiation alone. Results of RTOG 92–02 indicate the subgroup of clinical T2c-T4 patients with Gleason 8–10 who received long-term androgen suppression therapy (AST) had improved survival and likewise survival benefit was demonstrated with long-term AST in a phase III EORTC study that included a minority of patients eligible based on high grade Gleason Score alone.